The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Research and development | 3,131 |
| Selling, general and administrative | 4,767 |
| Total operating expenses | 7,898 |
| Net other (expense) income | -95 |
| Net loss from continuing operations | -7,993 |
| Stock based compensation | 564 |
| Depreciation | 5 |
| Amortization of debt discount and debt issuance costs | 97 |
| Non-cash interest expense | 48 |
| Change in fair value of derivative liability | 28 |
| Issuance of warrants for services | 93 |
| Amortization of right-of-use asset | 0 |
| Write-off offering costs related to unclosed financing arrangements | 143 |
| Prepaid expenses and other current assets | -78 |
| Other assets | 0 |
| Accounts payable | 139 |
| Accrued expenses | 235 |
| Lease liabilities | 0 |
| Net cash used in operating activities - continuing operations | -6,619 |
| Net cash used in operating activities - discontinued operations | -380 |
| Net cash used in operating activities | -6,999 |
| Issuance of note receivable | 124 |
| Acquisition of property and equipment | 38 |
| Acquisition of licensed technology | 543 |
| Net cash used in investing activities | -705 |
| Issuance costs in connection with senior convertible note | 172 |
| Proceeds from issuance of common stock, net of issuance costs | 2,337 |
| Proceeds from issuance of common stock and warrants, net of issuance costs | 0 |
| Proceeds from issuance of preferred stock and warrants, net of issuance costs | 16,209 |
| Proceeds from warrant exercises | 109 |
| Offering costs in advance of sale of common stock | 136 |
| Net cash provided by financing activities | 18,347 |
| Net increase (decrease) in cash and cash equivalents | 10,643 |
| Beginning of period | 2,002 |
| End of period | 12,645 |
| Less cash and cash equivalents included in discontinued operations | 0 |
| Cash and cash equivalents included in continuing operations | 12,645 |
Tivic Health Systems, Inc. (TIVC)
Tivic Health Systems, Inc. (TIVC)